Top

BMC Urology

Published in:

Open Access 01-12-2021 | Biomarkers | Research

EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker

Authors: Yue Yang, Hanchao Zhang, Zhengdao Liu, Faliang Zhao, Guobiao Liang

Published in: BMC Urology | Issue 1/2021

Abstract

Background

Bladder cancer (BLCA) is a malignant urothelial carcinoma and has a high mortality rate. EPDR1 (ependymin related 1) is a type II transmembrane protein and related to calcium-dependent cell adhesion.

Methods

We explored the potential oncogenic roles of EPDR1 in BLCA basing on the multiple public datasets.

Results

We found that EPDR1 expression had a significant difference in BLCA and adjacent normal bladder tissues, and the level of EPDR1was up-regulated with advanced tumor stage and metastasis in BLCA. Meanwhile, the high expression group of EPDR1 had a shorter OS compared to the low or medium expression-group. Furthermore, EPDR1 expression was associated with tumor-infiltrating immune cells (TIICs), including NK cells, CD8 + T cells, CD4 + T cells, Macrophages cells, and so on. Moreover, EPDR1 also involved in several signaling pathways as well as PI3K/AKT pathway, Cytokine receptor interaction, and apoptosis.

Conclusion

EPDR1 can be used as a novel prognostic biomarker as well as an effective target for diagnosis and treatment in BLCA.

Richters A, Aben K, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–904.CrossRef

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef

Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4–34.CrossRef

Nakatsukasa K, Nishimura T, Byrne SD, et al. The Ubiquitin Ligase SCF (Ucc1) Acts as a Metabolic Switch for the Glyoxylate Cycle. Mol Cell. 2015;59(1):22–34.CrossRef

Nimmrich I, Erdmann S, Melchers U, et al. The novel ependymin related gene UCC1 is highly expressed in colorectal tumor cells. Cancer Lett. 2001;165(1):71–9.CrossRef

Apostolopoulos J, Sparrow RL, McLeod JL, et al. Identification and characterization of a novel family of mammalian ependymin-related proteins (MERPs) in hematopoietic, nonhematopoietic, and malignant tissues. DNA Cell Biol. 2001;20(10):625–35.CrossRef

Gimeno-Valiente F, Riffo-Campos AL, Ayala G, et al. EPDR1 up-regulation in human colorectal cancer is related to staging and favors cell proliferation and invasiveness. Sci Rep. 2020;10(1):3723.CrossRef

Chu C H, Chang SC, Wang HH, et al. Prognostic values of EPDR1 hypermethylation and its inhibitory function on tumor invasion in colorectal cancer. cancers (Basel), 2018,10(10).

Rosenberg EE, Gerashchenko GV, Hryshchenko NV, et al. Expression of cancer-associated genes in prostate tumors. Exp Oncol. 2017;39(2):131–7.CrossRef

10.

Liang X, Bai J, Chen B. Overexpression of EPDR1 has an antitumorigenic effect on breast cancer in vitro. Int J Clin Exp Pathol. 2020;13(10):2628–36.PubMedPubMedCentral

11.

Chen R, Zhang Y. EPDR1 correlates with immune cell infiltration in hepatocellular carcinoma and can be used as a prognostic biomarker. J Cell Mol Med. 2020;24(20):12107–18.CrossRef

12.

Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2019;51(2):411–2.CrossRef

13.

Bonneville R, Krook M A, Kautto E A, et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCO Precis Oncol, 2017,2017.

14.

Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615–25.CrossRef

15.

Cassetta L, Noy R, Swierczak A, et al. Isolation of mouse and human tumor-associated macrophages. Adv Exp Med Biol. 2016;899:211–29.CrossRef

16.

Crispen PL, Kusmartsev S. Mechanisms of immune evasion in bladder cancer. Cancer Immunol Immunother. 2020;69(1):3–14.CrossRef

17.

Cao R, Yuan L, Ma B, et al. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). Cancer Immunol Immunother. 2021;70(1):1–18.CrossRef

18.

Loh XY, Sun QY, Ding LW, et al. RNA-binding protein ZFP36L1 suppresses hypoxia and cell-cycle signaling. Cancer Res. 2020;80(2):219–33.CrossRef

19.

Barrows D, Feng L, Carroll TS, et al. Loss of UTX/KDM6A and the activation of FGFR3 converge to regulate differentiation gene-expression programs in bladder cancer. Proc Natl Acad Sci USA. 2020;117(41):25732–41.CrossRef

20.

Pietzak EJ, Bagrodia A, Cha EK, et al. Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol. 2017;72(6):952–9.CrossRef

Title: EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker
Authors: Yue Yang
Hanchao Zhang
Zhengdao Liu
Faliang Zhao
Guobiao Liang
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Biomarkers
Published in: BMC Urology / Issue 1/2021
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/s12894-021-00843-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Osteochondroma of the pubic symphysis causing hematuria: a case report and literature review

Do organic substances act as a degradable binding matrix in calcium oxalate kidney stones?

Buccal mucosal graft urethroplasty for anterior urethral stricture, experience from a low-income country

Incidental diagnosis of nonfunctional bladder paraganglioma: a case report and literature review

Metastatic renal cell carcinoma to pancreas and gastrointestinal tract: a clinicopathological study of 3 cases and review of literature

Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle-invasive bladder cancer: a propensity score-matched study